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Tsh receptor signaling abrogation 
by a novel small Molecule
Rauf Latif1*, Ronald B. Realubit2, Charles Karan2, Mihaly Mezei3 and Terry F. Davies1
1 Thyroid Research Unit, James J. Peters VA Medical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA, 
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Pathological activation of the thyroid-stimulating hormone receptor (TSHR) is caused by 
thyroid-stimulating antibodies in patients with Graves’ disease (GD) or by somatic and 
rare genomic mutations that enhance constitutive activation of the receptor influencing 
both G protein and non-G protein signaling. Potential selective small molecule antago-
nists represent novel therapeutic compounds for abrogation of such abnormal TSHR 
signaling. In this study, we describe the identification and in vitro characterization of a 
novel small molecule antagonist by high-throughput screening (HTS). The identification 
of the TSHR antagonist was performed using a transcription-based TSH-inhibition 
bioassay. TSHR-expressing CHO cells, which also expressed a luciferase-tagged CRE 
response element, were optimized using bovine TSH as the activator, in a 384 well plate 
format, which had a Z score of 0.3–0.6. Using this HTS assay, we screened a diverse 
library of ~80,000 compounds at a final concentration of 16.7 μM. The selection criteria 
for a positive hit were based on a mean signal threshold of ≥50% inhibition of control 
TSH stimulation. The screening resulted in 450 positive hits giving a hit ratio of 0.56%. A 
secondary confirmation screen against TSH and forskolin – a post receptor activator of 
adenylyl cyclase – confirmed one TSHR-specific candidate antagonist molecule (named 
VA-K-14). This lead molecule had an IC50 of 12.3 μM and a unique chemical structure. 
A parallel analysis for cell viability indicated that the lead inhibitor was non-cytotoxic at 
its effective concentrations. In silico docking studies performed using a TSHR trans-
membrane model showed the hydrophobic contact locations and the possible mode 
of inhibition of TSHR signaling. Furthermore, this molecule was capable of inhibiting 
TSHR stimulation by GD patient sera and monoclonal-stimulating TSHR antibodies. In 
conclusion, we report the identification of a novel small molecule TSHR inhibitor, which 
has the potential to be developed as a therapeutic antagonist for abrogation of TSHR 
signaling by TSHR autoantibodies in GD.
Keywords: Tsh receptor, small molecule, antagonist
Abbreviations: BD, Brownian dynamics; FSH, follicle-stimulating hormone; FSK, forskolin; HTS, high-throughput screening; 
LH, luteinizing hormone; MD, molecular dynamics; SML, small molecule ligands; TMH, transmembrane helix; TSHR, TSH 
receptor.
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inTrODUcTiOn
The TSH receptor (TSHR) is primarily expressed in the basolateral 
surface of thyroid follicular cells and induces thyroid cell growth, 
hormone synthesis, and hormone secretion and also happens to 
be a primary autoantigen in autoimmune thyroid disease; espe-
cially Graves’ disease (GD) (1–4). GD is one of the most common 
organ-specific autoimmune diseases with a prevalence of ~2% in 
the general population (5). It is an antibody and T cell-mediated 
disease where hyperstimulation of the thyroid gland leads to 
excess thyroid hormone production. The pathogenic effects of GD 
are driven, in part, by the interaction of stimulating antibodies to 
the TSHR, which bind to its large extracellular domain (ECD) (6). 
Such autoantibodies come in different varieties that can stimulate, 
block, or lead to apoptosis via induction of cellular stress (2, 7). 
In addition to its primary site on the thyroid cell, the TSHR is 
also expressed in a variety of extra thyroidal tissues where it is 
known to modulate target cell function, including fibroblasts and 
adipocytes and osteoclasts and osteoblasts (8–13). For example, 
there is evidence for a role of the TSHR in Graves’ orbitopathy 
and retro-orbital adipogenesis (13, 14) and as a negative regulator 
in bone remodeling (11). The presence of the TSHR in these and 
other extra thyroidal depots (10) makes it an important candidate 
receptor for several undefined roles secondary to the cascade of 
effects that may result from its chronic stimulation in GD.
In the last few years, small molecules have gained momentum 
as therapeutic options secondary to the development of large 
chemical libraries and robust high-throughput screening (HTS) 
assays (15). In addition to their low cost and ease to manufacture, 
they also have inherent chemical and biological advantages. These 
advantages include their ease in crossing plasma membrane bar-
riers and their in vivo stability due to their resistance to proteolytic 
enzymes. Small molecule agonists against the TSHR have been 
reported by others (16, 17), as well as ourselves (18). However, 
to date, only a single TSHR antagonist has been reported, which 
was found following chemical modification of an agonist, but its 
potency is only in the micro molar range (19). There is now a need 
to improve the potency of such molecules to achieve a therapeutic 
IC50 in the nano molar range (10−9M).
All small molecules interacting with the TSHR appear to 
permeate the cell and dock with distinct polar and non-polar 
residues within the hydrophobic pockets created by the helices 
of the transmembrane (TM) domain and exert a stimulatory 
or inhibitory effect by altering the interaction and movement 
of these helices (20, 21), thus acting as novel pharmacophores. 
This report describes the identification and in vitro characteriza-
tion of a small molecule antagonist to the TSHR selected by a 
chemical library screen using an in-house luciferase-based high-
throughput inhibition assay.
MaTerials anD MeThODs
Materials
Bovine TSH (1  IU/ml), human FSH (70  IU/ml), hCG (10  IU/
vial), and forskolin (FSK) were purchased from Sigma-Aldrich 
(St Louis, MO, USA). The Bright-Glo™ luciferase substrate (Cat 
# E2610) was purchased from Promega Corporation, Madison, 
WI, USA. The cell culture medium, DMEM, and Ham’s F12 
were purchased from Mediatech Inc., Manassas, VA, USA. Fetal 
bovine serum and fetal calf serum were purchased from Atlanta 
Biologicals, Flowery Branch, GA, USA. Additional amounts of 
lead compounds that were identified by screening were purchased 
from Enamine Inc., Cincinnati, OH, USA.
screening libraries
Three libraries were used in the screening: (1) Lead-Optimized 
Compound library (LOC) made up of 9,690 molecules, (2) 
Enamine library made of 60,638 molecules, and (3) Analyticon 
library made up of 10,000 molecules. All three libraries were 
specifically designed by the Columbia University HTS facility (22, 
23). A total of 80,328 molecules were screened as a single point, at 
a concentration of 16.7 μM. All potential hits were than analyzed 
by dose–response studies in triplicate.
cell lines Used
(a) CHO-HA-TSHR luciferase cells: For HTS, we used cells 
generated by transfecting the pGL4.29 [luc2P/CRE/Hygro] 
construct into a highly selected stable line of CHO cells 
expressing the human TSH receptor with an hemagglutinin 
(HA) tag at the N-terminus (CHO-HA-TSHR cells) that has 
been previously described and was selected as a stable line 
with hygromycin (18). The cells were cultured in Ham’s F-12 
medium with 10% fetal bovine serum (FBS) and 100  IU/
ml of penicillin, 100 μg/ml streptomycin, and 50 μg/ml of 
hygromycin.
(b) Murine Sertoli cell line TM4: These FSH receptor expressing 
cells were obtained from ATCC (CRL-1715) and cultured in 
DMEM: F12 medium (cat # 30-2006) with 2.5% FBS and 5% 
horse serum (ATCC; cat #30-2040).
(c) LH receptor-expressing cells: The specificity against the LH/
hCG receptor was tested using a stable line of rat LH/hCG 
receptor expressing HEK 293 cells that were kindly provided 
by Dr. K. M. J. Menon, University of Michigan, Ann Arbor, 
MI, USA. These cells were cultured in DMEM medium 
with 10% FBS and 100  IU/ml of penicillin and 100 μg/ml 
streptomycin.
hTs inhibition assay
This assay was based on the same principle as described previ-
ously (18) for screening of agonist molecules. Briefly, 15,000 
CHO-HATSHR Luci #1 cells [named TSHR-Glo cells (15)] were 
plated into white standard 384 wells at a volume of 30 μl in Ham 
F12 complete medium and incubated overnight at 37°C at >85% 
humidity. Library compounds were added at 16.7 μM to each well 
using a 384 nano-head (Perkin Elmer Inc.) and preincubated for 
1  h at 37°C prior to stimulant addition. The compound added 
wells were then stimulated with 5 μl corresponding to 20 μU of 
bovine TSH for 4 h. To determine the luciferase activity in these 
cells at the end of incubation, the wells received 13 μl of the sub-
strate Bright-Glo™. The luminescence was then measured using 
an EnVision multilabel reader (Perkin Elmer Inc.). In principle, 
activation of the TSHR by TSH results in Gsα-adenylate cyclase 
coupling and an increase in intracellular cAMP, which results in 
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FigUre 1 | inhibition assay for detection of Tshr antagonists and overview of positive hits. (a) The HTS luciferase assay that was developed for detection 
of antagonists against the TSHR was first tested for its TSH inhibitory activity using bovine TSH (10 and 100 μU) against a control antagonist. We screened a diverse 
chemical library of ~80,000 compounds for novel antagonists using this assay. (B) All positive hits were tested in parallel against TSH (y-axis) and forskolin (x-axis) as 
shown in this x–y plot. Molecules that showed >50% inhibition of TSH signal but 0 or <5% inhibition of forskolin signal were considered as potential inhibitors of the 
TSHR. Fourteen such randomly selected representative molecules are shown as green dots on this plot.
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the activation of CREB and its binding to the CRE element and 
subsequently induces the transcription of the luciferase gene and 
accumulation of the luciferase enzyme within the activated cells. 
Since the cells are preincubated with compounds that may inhibit 
the activation of Gsα-adenylate cyclase system, TSH activation 
of the receptor would be inhibited if the compound is a specific 
TSHR antagonist. However, the screen may result in false posi-
tives that inhibit activation of adenylate cyclase directly and thus 
inhibiting cAMP generation. Therefore, hits that are picked up 
in an initial screen must, then, be tested against FSK to rule out 
such false positives.
Throughout the screen, the signal to background ratio was 
linear and the mean CV was 5.4% and the Z′ factor was in the 
range of 0.3–0.6 based on the positive control Antag3 (19) (also 
kindly provided by Dr. M. Gershengorn, NIH, Bethesda, MD, 
USA) used in the plate. This exceeded the commonly accepted 
threshold for validation of high-throughput assays (24). When we 
challenged the cells with two different concentrations of bovine 
TSH (10 and 100 μU) (Figure  1A), we found that stimulation 
with 10 μU of TSH gave an inhibition of ~30–40% compared with 
less than 10% inhibition observed by stimulation with 100 μU of 
TSH. However, on optimization of the HTS, we found 20 μU TSH 
as the best stimulation because it gave similar inhibition in the 
HTS. We used an arbitrary fixed criteria for selecting molecules 
as positive hits if they showed ≥50% inhibition of TSH activity. 
Medium with <1% of DMSO was the negative control, whereas 
the control molecule with TSH and just TSH alone acted as posi-
tives in the assay for normalization of the signal and identification 
of positives hits.
confirmatory assays
Dose–responses of the lead molecules were performed against 
TSH and FSK using a Tecan HP digital dispenser by following a 
similar protocol as described. All data points of the dose–response 
curves were fitted using Prism 5.0. A fluorescent viability assay 
(Cell Titer-Fluorviability assay, Promega Inc.) was also performed 
in the same experiment to assess toxicity of the molecules.
Docking of lead Molecule on the Tshr 
Transmembrane Domain
Docking of the lead molecules was performed on a homology 
model of the TSHR-TMD based on rhodopsin (PDB:1F88). 
This template was chosen because of the low root-mean-square 
deviation (RMSD) values between the backbone of the TM heli-
ces of the TSHR model and that of the rhodopsin X-ray crystal 
structure (25) and fits the experimental parameters that we have 
previously described (26). The initial homology model of rho-
dopsin was obtained from the Uniprot server.1 The conformations 
of the extracellular loops were constructed with the Monte Carlo 
method (27). The 3D geometries of the molecules in Tripos’mol2 
format were generated with MarvinSketch.2 Docking was carried 
out using the docking, Autodock 4. The docking results were 
analyzed using DOCKRES and other supporting script tools (28).
serum samples
Serum samples used in this study were unidentifiable stored 
samples originally collected with the full consent of patients.
statistical analyses
All curve fitting and EC50 calculations were performed using 
GraphPad Prism version 5.02, and statistical differences for P 
values were calculated using one-tailed t test using Graph Pad 
In Stat software.
resUlTs
evaluation of the hTs luciferase-Based 
inhibition assay for screening and 
identification of Tshr-specific inhibitors
Using this HTS inhibition assay, we screened a total of 80,328 
molecules consisting of all three libraries as described earlier at a 
1 http://www.uniprot.org 
2 http://www.chemaxon.com 
FigUre 2 | evaluation of the hTs assay. (a) The Z factor was calculated 
using the positive control and basal control responses in each plate as per 
the formula described by Zhang et al (24) (B) The signal to background ratio 
was obtained using the total signal from the positive control well against 
those wells receiving medium plus DMSO. (c) The coefficient of variation  
(% CV) was calculated as the SD from the wells with the basal medium 
divided by the wells of the positive control. The data indicated that the HTS 
assay performed within the limits of a reliable screening.
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single concentration of 16.7 μM. We obtained 450 positives hits 
from this initial screen with a hit ratio of 0.56%. The performance 
of the assay throughout the screen is indicated by the Z score, 
signal to background ratio, and % CV plots (Figure 2). Further, to 
eliminate false positives and to obtain a secondary confirmation 
of the positives, we performed a secondary testing at 16.7 μM 
against 20 μU of TSH and 10 μM of FSK. Figure 1B is an x–y 
plot showing the results of such a screen where percent of TSH 
luciferase signal is indicated in the y-axis with percent of FSK 
signal in the x-axis. Molecules that showed 50% or greater inhibi-
tion of TSH and none or very little inhibition against FSK were 
generally regarded as potential inhibitory molecules specific to 
the TSHR and marked out for dose–response analysis. Fourteen 
such potential hits (marked by green circles) in Figure  1B are 
represented in the plot.
selection of a specific Tshr antagonist
Using our selection criteria, we identified 14 molecules as poten-
tial inhibitory molecules. These 14 molecules were further tested 
in triplicate at 16.7 μM against stimulation with 20 μU of TSH 
and 10 μM of FSK to confirm their specific inhibitory potency 
as indicated (Figure 3). Three molecules (marked by the arrows) 
appeared to have potential and were subjected to dose–response 
studies against TSH and FSK.
Dose–responses of each of the selected molecules (K14, 
L13 and F9) are represented in the different panels in Figure 4 
along with one non-specific molecule (D22). The dose–response 
curves of the molecules strongly indicated that K14 had a 
30–40% inhibition of TSH with negligible inhibition of FSK and 
low cytotoxicity compared with molecules L13, F9, or D22. Since 
K14 showed specific inhibition in the range examined, this was 
regarded as our most specific lead antagonist against the TSHR 
(now referred to as VA-K-14). VA-K-14 had an IC50 = 12.32 μM, 
and, although it was specific to the TSHR, it appeared to have a 
narrow inhibitory range.
specificity analysis of Va-K-14
We, next, analyzed the specificity of VA-K-14 against other 
closely homologous glycoprotein receptors – the FSH receptor 
and LH/hCG receptor – using a cAMP femto HTRF bioassay 
(Cat # 62AM5PEB, Cisbio Inc.). For the LH receptor cells, we 
used HEK 293 cells transfected with the rat LH/hCG receptor, 
and, for the FSH receptor, we used a murine Sertoli cell line 
(TM4), which expresses the FSHR and responds to human FSH 
in a dose-dependent manner. Inhibition of intracellular cAMP 
generation was measured after stimulation of these cells with 
maximal responsive doses of their respective ligands (TSH, FSH, 
and hCG), after preincubation with VA-K-14 (0.01–100 μM). The 
TSHR-CHO cells were stimulated with 20 μU of bovine TSH, 
LH/hCC receptor cells with 1000  μU/ml of hCG, and Sertoli 
cells were stimulated with 700  μU/ml of human FSH, which 
had previously been titrated for optimum stimulation of cAMP 
under our experimental conditions (18). VA-K-14 showed more 
than 40% inhibition on the TSHR-expressing cells (Figure 5A). 
VA-K-14 showed a minor degree of inhibition (~10–15%) against 
the hCG/LH and FSH receptor-expressing cells, suggesting small 
molecules that are strong antagonists against the TSHR might 
have inhibitory effects against their homologous glycoprotein 
hormone receptors as seen previously (19).
Define the Binding sites by Molecular 
Docking
Inhibitory small molecule ligands are usually allosteric modula-
tors of GPCRs (29). Figure  5B shows the molecular structure 
of VA-K-14 – which is N-methyl-4-(2-phenyl-1H-indol-3-yl)-
thiazole-2-amine with a molecular weight of 305.406  Da. This 
molecule meets the Lipinski rule-of-five criteria (30) with an xlog 
P of 4.34 and tPSA of 40. It is dissimilar in structure to the one 
published TSHR antagonist (19).
We examined the binding sites of VA-K-14 to the TM region of 
the TSHR by in silico docking, using a structure of the TSHR-TM 
region developed in our laboratory by homology modeling based 
on the rhodopsin crystal structure (26) and Monte Carlo simula-
tions. By examining the top scoring docking poses generated by 
Autodock 4 and Autodock-Vina (all clustered at the same region 
of the extracellular hydrophobic pocket), we were able to deduce 
the putative contact residues within the TSHR-TM domain 
(Figure 5C). Docking analysis indicated that VA-K-14 is likely to 
make contact with residues Asn 483 (N483) and Trp 488 (W488) 
in ECL1 and Leu 468 (L468) on TMH1, Thr500 (T500) in TMH3, 
FigUre 3 | hit validation. This bar graph illustrates the testing of the fourteen chosen compounds for inhibition of TSH and forskolin (FSK) signaling 
(mean ± SEM). The percent inhibition of the maximum TSH or forskolin signal is represented on the y-axis. Indicated by the arrows were three potentially specific 
candidates that showed minimal inhibition of forskolin (black bars) but significant inhibition of TSH (red bars). These three candidate molecules were then subjected 
to dose–response analyses.
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FigUre 4 | Testing of selected lead molecules. These four panels indicate the dose–responses of three likely (from Figures 3 and 1) and one control unlikely 
lead molecule against TSH (red) and FSK (gray). VA-K14 was the only molecule that effectively inhibited the TSH signal and had no inhibition for FSK compared with 
L13, F9, and D22. The toxicity of these molecules was tested by measuring viability (black) using the Cell titer Fluor assay within the same assay.
6Latif et al. TSH Receptor Antagonist
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and Val 664 (V664) in TMH7 within the previously described 
hydrophobic pocket of the TMD (20, 21).
inhibition of Tshr antibodies
We first tested our luciferase assay for inhibition of signal 
response in the presence of potent blocking TSHR antibody that 
binds to the ectodomain of the receptor. Figure  6A shows the 
inhibition of luciferase signal observed on stimulation of cells 
with 50 μU of TSH in the absence of antibody (gray bar) and in 
the presence of increasing doses of a monoclonal human TSHR 
blocking antibody (K1-70) (31) (kindly provided by Dr Bernard 
Rees Smith, RSR Ltd., Cardiff, Wales). Nearly 40% inhibition of 
stimulation was observed at 10 μg of the K1-70 blocking antibody.
In order to assess if our lead antagonist VA-K-14 was capable 
of inhibiting stimulating TSHR antibodies in GD patient sera, 
we tested a panel of 14 Graves’ sera (diluted 1:10) in the absence 
and presence of 10  μM of VA-K-14. We observed variable 
degrees of inhibition of stimulation although all the sera were 
inhibited to some degree (Figure  6B). VAK-14 was also effec-
tive in inhibiting a widely used human monoclonal-stimulating 
antibody [M22, also kindly provided by Dr Bernard Rees Smith, 
RSR Ltd., Cardiff, Wales (32)] and a hamster-derived stimulating 
monoclonal antibody (MS-1) (33) (Table 1).
combining Two structurally Dissimilar 
antagonists
When we compared VA-K-14 with the control antagonist (Antag 
3), which is structurally dissimilar and makes contact with 
disparate residues in the TMD region, we found similar degrees 
of inhibition at concentrations between 1 and 100 μM, but com-
parison of the area under the curves (AUC) showed that the two 
molecules were significantly (P = 0.003) different in their degree 
of inhibition (Figure  7A). This significant difference in their 
dose–response relationships also most likely indicated their bind-
ing to different residues in the TSHR-TM domain. Since VA-K-14 
and Antag 3 have different binding sites within the hydrophobic 
pocket of the receptor, we examined the effect on inhibition of 
stimulation by combining the two. This analysis clearly indicated 
that combining two antagonists did not enhance the degree of 
inhibition (data not shown), suggesting that the complex dynamic 
molecular interactions that the small molecules make with the 
receptor allosteric site has limits to its distortion potential.
A
B
C
FigUre 5 | (a) Specificity and TSHR docking of the lead molecule (a) CHO-TSHr stable cells, HEK-LH/CGr stable cells, and FSHr- Sertoli cells (TM4) were 
stimulated with the maximum effective concentrations of their respective ligands as described in Section “Materials and Methods” for 1 h at 37°C in the presence of 
1 mM IBMX and increasing concentrations of our lead antagonist VA-K-14. As indicated by the red line, VA-K-14 inhibited TSH by 75% at 10 μM in contrast to an 
inhibition of 10–15% with the hCG/LHr cells and FSHr cells. These data were average plots of two independent experiments performed in triplicate. (B) The 
structure of VA-K-14 is N-methyl-4-(2-phenyl-1H-indol-3-yl)-thiazole-2-amine with a molecular weight of 305.406 Da. (c) In silico docking performed on the 
homology model of the TSHR transmembrane domain (26) using Autodock 4 strongly suggested that VA-K-14 docks into the hydrophobic pocket of the 
TSHR–TMD, thus making contact with two residues in extracellular loop 1 (ECL1) (residues Asparagine 483 and tryptophan 488) and further contacts with Leucine 
468 on TMH 2, Threonine 500 on TMH 3, and Valine 664 on TMH 7.
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Mechanism of Va-K-14 action
Docking analysis indicated that VA-K-14 makes contact with 
tryptophan 488 (W488) on ECL1 and a second contact with 
Valine 664 (V664) in TMH 7 by launching itself in the hydropho-
bic pocket formed by helices of the TSHR TMD (Figure 7B). It is 
known that W488 is an important residue of a naturally occurring 
inactivating mutation (34) and V664 of helix 7 is a critical partner 
with Isoleucine 568 (35) on ECL2 which helps in stabilization of 
the receptor conformation.
DiscUssiOn
Hyperthyroid GD is currently treated with antithyroid drugs, 
radioactive iodine, or surgery (36). However, these modes of 
treatment though effective are not without complications and 
antithyroid drug treatment is commonly followed by relapses 
(37, 38). Antithyroid drugs can also cause severe or even life-
threatening complications. Nevertheless, there have been few 
attempts to develop newer drugs that would be more effective. 
Small molecule antagonists that can inhibit signaling of the TSHR 
do, however, have serious potential as novel therapeutic options. 
We have previously reported the development of two lead small 
molecule agonists against the TSH receptor (18). In this study, we 
describe the in vitro characterization of a novel TSHR antagonist 
identified by high-throughput screening using a transcriptional-
based luciferase inhibition assay.
Though the TSHR is promiscuous in engaging several G 
proteins (39) and β-arrestin 1 and 2 (40–42), it is known that the 
predominant signal that comes from the receptor is via engage-
ment of the Gs subclass of G protein, which leads to the genera-
tion of second messenger cAMP. We have previously exploited 
this major signaling pathway to develop a sensitive HTS assay 
for TSHR agonist detection, known as the TSHR-Glo assay (15). 
We extended the stimulation assay by first pre-incubating the 
cells with the library compounds and, then, stimulating them 
with an optimized dose of bovine TSH for 4 h before reading the 
luciferase signal. Though the inhibition HTS assay was not robust 
in its performance as just judged by Z factor score, it was effective 
enough to detect 30–40% inhibition of low dose TSH stimulation 
and maintained a fairly consistent Z score (Figures 1A and 2). 
However, on screening a diverse library of compounds of 80,328 
molecules using this HTS assay, we identified only one lead mol-
ecule (VA-K-14) that was specific to the TSHR and failed to show 
A B
FigUre 6 | inhibition of gD sera by Va-K-14. (a) The bar graph shows the inhibition of TSH signal (50 μU/ml) by a human blocking monoclonal antibody 
(K1-70). Increasing doses of antibody caused inhibition of TSH signal. Significant inhibition (P = 0.0116) was observed at 10 μg/ml of K1-70 monoclonal antibody. 
This suggested that the inhibition assay was capable of measuring TSHR-Ab inhibition of cAMP generation. (B) We tested a series of GD serum samples at 1:10 
dilution for inhibition by VA-K-14. The cells were first preincubated with 10 μM of VA-K-14 or just medium and then challenged with diluted serum in triplicate wells. 
As indicated here, there was a varied degree of inhibition observed in the presence of 10 μM of VA-K-14 (black filled bars) compared with untreated serum (gray 
bars) with the luciferase assay. As seen here, P3 and P5 showed the most significant suppression of their stimulating responses in the presence of antagonist, but 
inhibition of P12 was poor.
TaBle 1 | Dose-dependent inhibition of M22 and Ms1 by molecule Va-K-14.
Dose of Va-K-14 (µM) M22 (% change) Ms1 (% change)
0 100 100
0.1 99.93 ± 2.36 95.64 ± 4.56
1 83.63 ± 3.38 90.73 ± 0.91
10 68.36 ± 0.49 64.47 ± 1.00
Note: the dose of M22 used for stimulation was 1.5 µg final and that of MS-1 was 
15 µg, final. The assay was carried out with 15,000 cells/well in 348 well plate using 
CHOTSHR luciferase cells.
8Latif et al. TSH Receptor Antagonist
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ECL1
ECL2
ECL3
I568
VA-K-14
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A B
FigUre 7 | Mechanistic action of Va-K-14. (a) Indicated in this dose–response graph is a comparison of our lead molecule VA-K-14 and the reported Antag3 in 
order to compare their inhibition of TSH signaling. Although the two molecules are structurally different, they clearly have the potential to inhibit TSH action in a 
similar manner. However, the area under the curve calculation of VA-K-14 versus Antag3 indicated VA-K-14 to be significantly different in its inhibitory characteristics 
of the TSH response in this assay. (B) This diagram indicates the possible mechanism for the inhibitory effect of VA-K-14 on binding to the hydrophobic pocket in 
the TMD of the TSHR. The molecule contacts tryptophan 488 (W488) in ECL1 (pink) and valine 664 (V664) on helix 7 (blue). W488 is a naturally occurring 
inactivating mutation where V664 is a critical partner with Isoleucine 568 in ELC2 in stabilization of the receptor conformation. Thus, it would seem that this charge 
interaction network formed by VA-K-14 in the hydrophobic pocket must play a role in stabilizing an inactive conformation of the receptor transmembrane and, thus, 
leading to dampening of the signal.
any inhibition of FSK – a post receptor activator of cAMP – even 
in dose–response analysis (Figure 4).
Since the TM domain of major GPCR’s, especially the gly-
coprotein hormone receptor family, such as the FSH and hCG/
LH receptors, is quiet homologous (43) in their sequence, it was 
important to examine receptor specificity of the lead small mol-
ecule. Using cells that express the FSH and LH receptor cells, we 
examined the specificity of our lead molecule VA-K-14. Though 
a potent inhibitor of TSHR, it also showed minor inhibition of 
cAMP generation against FSH and LH receptor bearing cells at 
the highest effective concentrations as seen with the previously 
reported antagonist (Antag 3) (19). The homologous nature of 
the TM domain of these receptors may cause such reactivity to 
be inevitable, and a potent antagonist, which was reported previ-
ously to be in the nanomolar range (44), was also found to lack 
all specificity against the TSHR and, thus, could not be developed 
further. But, it is known that functional ability of the allosteric 
modulators against the TSHR are defined by the contact residues 
within the TM domain (20), and the pharmacophore property 
of small molecules can be altered by structural alteration of their 
scaffold as evidenced by the development of Antag 3 (19).
To examine the contact sites of our lead molecule (VA-K-
14), we docked the molecule with a well verified TM domain 
structural model that we previously developed on the rhodopsin 
template (26). From the docking studies, it was clear that VA-K-
14 docked in the hydrophobic pocket of the TSHR-TM domain 
making polar and non-polar contacts with residues asparagine 
483 (N483) and tryptophan 488 (W488) on the extracellular loop 
1 (ECL1) and leucine 468 (I468) on TM 2, threonine 500 (T500) 
on TM 3, and valine 664 (V664) in TM 7. The contact residues of 
this molecule in the hydrophobic pocket are different from those 
of our lead agonists (18) and were also different from Antag 3.
It is known that GPCR activation could involve the movement 
of helices, especially TM3 and TM6 (45–47), and modeling stud-
ies with mutational analyses have clearly outlined several residues 
within the hydrophobic pocket defined by the various helices of 
the TMD (20, 21, 48). Hence, the molecular property of allosteric 
small molecules will reside in the mosaic of interactions that such 
a molecule makes within the pocket, thus stabilizing an active 
or inactive state of the TSHR. It is known that residue W488 in 
ECL1 is a naturally occurring inactivating mutation (34) and 
V664 on TMH7 is a critical partner with I568 in ECL in stabiliz-
ing a native receptor conformation (35). Thus, from the docking 
data, we can hypothesize that VA-K-14, by interacting with these 
two residues, may stabilize an inactive form of the TSHR, leading 
to inhibition of TSH signaling. Furthermore, a recent study (49) 
using computation analysis and chemical crosslinking followed 
by mass spectrometry has also shown that rearrangement of the 
ECD/ECL1 is critical for TSHR activation. Thus, any allosteric 
molecule that could thwart such a rearrangement (50) would be 
a potential negative allosteric modulator (NAM).
In conclusion, we identified and characterized, in vitro, a new 
antagonist of the TSHR, which is a potential candidate for further 
development to provide a therapeutic option for controlling the 
action of auto antibodies to the TSHR in hyperthyroid GD and 
its related manifestations.
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